Annals of Oncology 11:S107-S111, 2000
© 2000 European Society for Medical Oncology
Symposium Articles |
Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens
1 Dana Farber Cancer Institute Boston, MA, USA
2 Massachusetts General Hospital, Harvard Medical School Boston, MA, USA
3 Cross Cancer Institute, University of Alberta Edmonton, Alberta, Canada
Correspondence to: S. P. Treon MD, PhD Division of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA E-mail: steven.treon{at}dfci.harvard.edu
Background: In view of the successful use of serotherapy in many B-cell malignancies, we and others have sought to identify tumor selective antigens for the serotherapy of plasma cell dyscrasias (PCD) including multiple myeloma (MM), and Waldenstrom's macroglobulinemia (WM). We recently identified Muc-1 core protein as a MM selective antigen. Though Muc-1 core protein is abundantly expressed on most MM plasma cells, expression of this antigen can be absent, or weak on some plasma cells which could potentially result in the selection of Muc-1 core protein negative clones following serotherapy of PCD. In addition to Muc-1 core protein, we have also been examining the use of CD20 directed serotherapy for PCD.
Design: As part of these efforts, we recently initiated a phase II clinical trial examining the use of Rituximab (Rituxan, MabThera) as a single agent in MM patients; as well several WM patients have been treated with Rituximab at our Institutions.
Results: In previous studies, we have shown that CD20 is abundantly expressed on the plasma cells of most WM patients; in contrast, CD20 is expressed on plasma cells from a minority of MM patients, and in these patients expression of CD20 can be weak or heterogeneous with both CD20$ and CD20– plasma cells present. As such, we have sought out clinically useful inducers of Muc-1 core protein, and of CD20 on malignant plasma cells.
Conclusions: These efforts resulted in the identification of dexamethasone (Dex) as a potent inducer of Muc-1 core protein on MM plasma cells, and interferon-
(IFN-) as a potent inducer of CD20 on MM plasma cells and B-cells. Importantly, these agents induced their respective antigens at pharmacologically achievable doses.
B cells, CD20, core protein, dexamethasone, immunotherapy, interferon-gamma, Muc-1, multiple myeloma, plasma cells, Rituximab
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. F. Smit, J. P.A.M. van Meerbeeck, P. Lianes, C. Debruyne, C. Legrand, F. Schramel, H. Smit, R. Gaafar, B. Biesma, C. Manegold, et al. Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975 J. Clin. Oncol., November 1, 2003; 21(21): 3909 - 3917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. V. N. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, M. Domine, F. Cardenal, J. M. Sanchez, P. H. Gumerlock, M. Taron, et al. Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2002; 8(7): 2286 - 2291. [Abstract] [Full Text] [PDF]
|
|